The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France

Key Points

• Evaluate the effect of elexacaftor-tezacaftor-ivacaftor on lung transplant needs for cystic fibrosis.
• Reviewed transplant data for cystic fibrosis patients in France
• Analyzed response to elexacaftor-tezacaftor-ivacaftor
• Assessed indications for first-time and re-transplantation
• ETI reduced need for first-time lung transplant but did not eliminate it
• Indications persist for patients who respond poorly to ETI
• Re-transplantation remains viable for select cases with chronic lung issues